🇺🇸 FDA
Patent

US 10849885

Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

granted A61KA61K31/4245A61K47/02

Quick answer

US patent 10849885 (Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy) held by PTC THERAPEUTICS, INC. expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/4245, A61K47/02, A61K47/10, A61K47/12